. 2021 Nov;13(11):6453–6467. doi: 10.21037/jtd-21-961

Table 2. Current clinical trials of LAMA/LABA FDCs.

LAMA/LABA FDCs	Clinical trials
GLY/IND	NCT01120691 (SPARK); NCT01202188 (SHINE); NCT01727141 (FLIGHT1); NCT01712516 (FLIGHT2); NCT01529632 (BEACON); NCT01709903 (LANTERN); NCT01315249 (ILLUMINATE); NCT01782326 (FLAME)
UMEC/VI	NCT01313637; NCT01316900; NCT01316913; NCT01313650; NCT01716520; NCT01491802
GFF	NCT01587079; NCT01854645 (PINNACLE 1); NCT01854658 (PINNACLE 2)
TIO/OLO	NCT01431274 (TONADO 1); NCT01431287 (TONADO 2); NCT01525615 (TORRACTO); NCT01533922 (MORACTO^TM 1); NCT01533935 (MORACTO^TM 2); NCT01559116; NCT01536262
ACL/FF	NCT01572792 (AUGMENT); NCT01462942 (ACLIFORM); NCT01437540; NCT01049360 (LAC-MD-27)
TIO/FF	NCT02988869

LAMA, long-acting muscarinic antagonist; LABA, long-acting β agonist; FDC, fixed-dose combination; GLY/IND, glycopyrronium/indacaterol; UMEC/VI, umeclidinium/vilanterol; GFF, glycopyrrolate/formoterol fumarate; TIO/OLO, tiotropium/olodaterol; ACL/FF, aclidinium/formoterol; TIO/FF, tiotropium/formoterol.